These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

457 related items for PubMed ID: 30122651

  • 1. Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media.
    Iino Y, Takahashi E, Ida S, Kikuchi S.
    Auris Nasus Larynx; 2019 Apr; 46(2):196-203. PubMed ID: 30122651
    [Abstract] [Full Text] [Related]

  • 2. Successful treatment of eosinophilic otitis media associated with severe bronchial asthma with an anti-IL-5 monoclonal antibody, mepolizumab.
    Suzaki I, Kimura Y, Tanaka A, Hirano K, Ishibashi A, Mizuyoshi T, Ando I, Kitajima T, Watanabe S, Hinohira Y, Kobayashi H.
    Auris Nasus Larynx; 2019 Feb; 46(1):141-146. PubMed ID: 29909018
    [Abstract] [Full Text] [Related]

  • 3. Dupilumab therapy for patients with refractory eosinophilic otitis media associated with bronchial asthma.
    Iino Y, Sekine Y, Yoshida S, Kikuchi S.
    Auris Nasus Larynx; 2021 Jun; 48(3):353-360. PubMed ID: 32943257
    [Abstract] [Full Text] [Related]

  • 4. Effect of omalizumab on biomarkers in middle ear effusion in patients with eosinophilic otitis media.
    Iino Y, Hara M, Hasegawa M, Matsuzawa S, Shinnabe A, Kanazawa H, Yoshida N.
    Acta Otolaryngol; 2014 Apr; 134(4):366-72. PubMed ID: 24628335
    [Abstract] [Full Text] [Related]

  • 5. Clinical efficacy of anti-IgE therapy for eosinophilic otitis media.
    Iino Y, Hara M, Hasegawa M, Matsuzawa S, Shinnabe A, Kanazawa H, Yoshida N.
    Otol Neurotol; 2012 Sep; 33(7):1218-24. PubMed ID: 22825324
    [Abstract] [Full Text] [Related]

  • 6. Bone conduction hearing level in patients with eosinophilic otitis media associated with bronchial asthma.
    Iino Y, Usubuchi H, Kodama K, Takizawa K, Kanazawa T, Ohta Y.
    Otol Neurotol; 2008 Oct; 29(7):949-52. PubMed ID: 18758390
    [Abstract] [Full Text] [Related]

  • 7. Risk factors associated with severity of eosinophilic otitis media.
    Kanazawa H, Yoshida N, Yamamoto H, Hara M, Hasegawa M, Matsuzawa S, Shinnabe A, Iino Y.
    Auris Nasus Larynx; 2014 Dec; 41(6):513-7. PubMed ID: 25199747
    [Abstract] [Full Text] [Related]

  • 8. Eosinophil chemoattractants in the middle ear of patients with eosinophilic otitis media.
    Iino Y, Kakizaki K, Katano H, Saigusa H, Kanegasaki S.
    Clin Exp Allergy; 2005 Oct; 35(10):1370-6. PubMed ID: 16238798
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A.
    Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
    [Abstract] [Full Text] [Related]

  • 10. New Insights into Eosinophilic Otitis Media.
    Kanazawa H, Yoshida N, Iino Y.
    Curr Allergy Asthma Rep; 2015 Dec; 15(12):76. PubMed ID: 26546407
    [Abstract] [Full Text] [Related]

  • 11. Diagnostic criteria of eosinophilic otitis media, a newly recognized middle ear disease.
    Iino Y, Tomioka-Matsutani S, Matsubara A, Nakagawa T, Nonaka M.
    Auris Nasus Larynx; 2011 Aug; 38(4):456-61. PubMed ID: 21251776
    [Abstract] [Full Text] [Related]

  • 12. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study.
    Pelaia C, Busceti MT, Solinas S, Terracciano R, Pelaia G.
    Pulm Pharmacol Ther; 2018 Dec; 53():1-5. PubMed ID: 30217438
    [Abstract] [Full Text] [Related]

  • 13. Use of IL-5 Inhibitor Benralizumab as a Novel Therapy for Eosinophilic Otitis Media: Clinical Capsule and Review of Literature.
    Chow K, Cosetti MK.
    Otol Neurotol; 2020 Feb; 41(2):e238-e240. PubMed ID: 31923159
    [Abstract] [Full Text] [Related]

  • 14. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
    Hilvering B, Xue L, Pavord ID.
    Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
    [Abstract] [Full Text] [Related]

  • 15. Eosinophilic inflammation in the middle ear induces deterioration of bone-conduction hearing level in patients with eosinophilic otitis media.
    Iino Y, Usubuchi H, Kodama K, Kanazawa H, Takizawa K, Kanazawa T, Ohta Y.
    Otol Neurotol; 2010 Jan; 31(1):100-4. PubMed ID: 19816234
    [Abstract] [Full Text] [Related]

  • 16. Eosinophilic otitis media: a new middle ear disease entity.
    Iino Y.
    Curr Allergy Asthma Rep; 2008 Nov; 8(6):525-30. PubMed ID: 18940145
    [Abstract] [Full Text] [Related]

  • 17. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
    Pelaia C, Vatrella A, Busceti MT, Gallelli L, Terracciano R, Savino R, Pelaia G.
    Drug Des Devel Ther; 2017 Nov; 11():3137-3144. PubMed ID: 29133975
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness of instillation of triamcinolone acetonide into the middle ear for eosinophilic otitis media associated with bronchial asthma.
    Iino Y, Nagamine H, Kakizaki K, Komiya T, Katano H, Saruya S, Kodera K.
    Ann Allergy Asthma Immunol; 2006 Dec; 97(6):761-6. PubMed ID: 17201235
    [Abstract] [Full Text] [Related]

  • 19. Eosinophilic otitis media; state-of-the-art diagnosis and treatment.
    Iino Y.
    Auris Nasus Larynx; 2023 Aug; 50(4):479-489. PubMed ID: 36528403
    [Abstract] [Full Text] [Related]

  • 20. A real-life cohort of mepolizumab treatment in severe eosinophilic asthma.
    Laorden D, Hernández I, Domínguez-Ortega J, Romero D, Álvarez-Sala R, Quirce S.
    Eur Ann Allergy Clin Immunol; 2024 Jul; 56(4):169-175. PubMed ID: 36927725
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.